08:47 AM EDT, 04/21/2026 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) said Tuesday that data from a phase 1b/2a trial evaluating EP-104GI to treat eosinophilic esophagitis showed a reduction in tissue health and symptom data.

The biotech firm said patients in cohort 9 of the trial demonstrated a "robust response" in tissue health and symptom response compared with their baseline levels.

Eosinophilic esophagitis is an inflammatory-mediated disease that creates pain and difficulty swallowing food for patients.

"This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI," Chief Executive James Halliwell said in a statement.